Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug
Dawoud, M., Sediek, M., Hany, A., Ahmed, S., Kamal, N. (2024). Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug. EKB Journal Management System, 28(5), 40-46. doi: 10.21608/egyfs.2024.388588
Mariam Dawoud; Mona Mohamed Sediek; Ayman Hany; Shaimaa Ahmed; Nada Kamal. "Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug". EKB Journal Management System, 28, 5, 2024, 40-46. doi: 10.21608/egyfs.2024.388588
Dawoud, M., Sediek, M., Hany, A., Ahmed, S., Kamal, N. (2024). 'Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug', EKB Journal Management System, 28(5), pp. 40-46. doi: 10.21608/egyfs.2024.388588
Dawoud, M., Sediek, M., Hany, A., Ahmed, S., Kamal, N. Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug. EKB Journal Management System, 2024; 28(5): 40-46. doi: 10.21608/egyfs.2024.388588

Effect of metformin on maternal and neonatal outcomes in pregnant obese diabetic patients: New potentials for an old drug

The Egyptian Journal of Fertility and Sterility
Volume 28, Issue 5 - Serial Number 11106352, September 2024, Page 40-46  XML PDF (228.52 K)
Document Type: Original Article
DOI: 10.21608/egyfs.2024.388588
View on SCiNiTO View on SCiNiTO
Authors
Mariam Dawoud1; Mona Mohamed Sediek2; Ayman Hany3; Shaimaa Ahmed4; Nada Kamal email 2
1Associate Professor of Obstetrics and Gynecology, Faculty of Medicine, Cairo University
2Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Cairo University
3Professor of Obstetrics and Gynecology, Faculty of Medicine, Cairo University
4Obstetrics and Gynecology Specialist
Abstract
Background: Pregnancy complicated by diabetes whether gestational or pregestational diabetes, could be associated with adverse maternal and neonatal outcomes; if optimum glycemic control was not achieved. Metformin is an insulin sensitizing drug that has been approved for treatment of gestational diabetes and type II pregestational diabetes. In this study, we have studied the role and effectiveness of metformin in improving glycemic control and the prevention of maternal and neonatal adverse outcomes in obese pregnant diabetic women.   
Patient and Methods: This was a prospective cohort study that included 189 obese pregnant diabetic women recruited to Kasr Al Aini Obstetrics and Gynecology department over the period from September 2022 till March 2023. The study population included three groups according to the treatment modality; metformin only group, metformin and insulin group and insulin only group.  
Results: The use of metformin was associated with significant reduction in the incidence of preeclampsia and neonatal lactic acidosis with a p value 0.033 and 0.002 respectively. However, use of metformin whether alone or in addition to insulin, compared to insulin alone was not shown to be superior in improving glycemic control, or reduce adverse neonatal outcomes..  
Conclusion: Metformin use in obese diabetic pregnant women improves maternal and neonatal outcomes. 
Keywords
Keywords: Metformin; Diabetes mellitus; pregnancy; Obesity. 
Statistics
Article View: 129
PDF Download: 39